High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

BACKGROUND. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial. PATIENTS AND METHODS. We analyzed 262 patients with centralized basal Ki67 immun...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton-Torres, Antonio, Sanchez-Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García-Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba-Rodriguez, Juan, Segui-Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2016
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746087/
https://ncbi.nlm.nih.gov/pubmed/26786263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0312
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars